NervGen Pharma Corp. Common stock

NGEN XNAS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

170M

Short interest (Jun 30)

3.8%

Net Short (Jul 27 ): 0.0%

Borrow Fee

0.94%

↓ 20.8%

Available Shares

↓ 11.2%

Price Chart

Company Overview

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Company Info

Exchange: NASDAQ

CIK: 0001751912

Asset Type: CS

Market Data

Market Cap: $173,452,591

Employees: 9

Status: Active

Short Interest

Current Borrow Fee 0.94%

Range: 0.92% - 0.94%

Available Shares 1M

Range: 1.2M - 1.3M

Recent Changes

Fee Change: ↑ 6.8%

Available Change: ↓ 18.8%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime